Proton therapy developer Ion Beam Applications (IBA) posted mixed results for its 2018 fiscal year (end-December 31).
The company reported 2018 revenue of 208.4 million euros ($236.9 million U.S.), down 11.9% from 236.5 million euros ($268.8 million) in 2017. IBA's revenue now comes solely from its proton therapy offerings; it attributed the revenue decrease to a slowdown in the market.
Last year, the company announced that it planned to explore options for its dosimetry business, which could include a sale, merger, or initial public offering. IBA is currently in active discussions regarding the sale of the division. It is now treating the division as a discontinued operation, but in 2018 the dosimetry unit had a net profit of 3.2 million euros ($3.6 million), up 29% from to 2.5 million euros ($2.8 million) in 2017.
